Hormone Replacement Therapy HRT TRT

by Dr. Randy Smith of Antiaging Atlanta

Reseach shows long term Testosterone Hormone Replacement Therapy not associatd with risk of High Grade Prostate Cancer.

 2015 Dec;194(6):1612-6. doi: 10.1016/j.juro.2015.05.099. Epub 2015 Jun 9.

Long-term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer.



To our knowledge no population based studies have been done to examine whether long-term exposure to testosterone therapy is associated with an increased risk of high grade prostate cancer. We examined whether exposure to testosterone during a 5-year period was associated with an increased risk of high grade prostate cancer and whether this risk increased in a dose-response fashion with the cumulative number of testosterone injections.


Using SEER (Surveillance, Epidemiology and End Results)-Medicare linked data we identified 52,579 mendiagnosed with incident prostate cancer between January 1, 2001 and December 31, 2006 who had a minimum of 5 years continuous enrollment in Medicare before the cancer diagnosis. We excluded patients diagnosed at death or after autopsy, those enrolled in a health maintenance organization in the 60 months before diagnosis and those with unknown tumor grade or tumor stage. In the 5 years before diagnosis 574 men had a history of testosterone use and 51,945 did not.


On logistic regression adjusting for demographic and clinical characteristics exposure to testosterone therapy was not associated with an increased risk of high grade prostate cancer (OR 0.84, 95% CI 0.67-1.05) or receipt of primary androgen deprivation therapy following diagnosis (OR 0.97, 95% CI 0.74-1.30). In addition the risk of high grade disease did not increase according to the total number of testosterone injections (OR 1.00, 95% CI 0.98-1.01).


Our finding that testosterone therapy was not associated with an increased risk of high grade prostate cancer may provide important information regarding the risk-benefit assessment for men with testosterone deficiency considering treatment.

Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.


SEER program; androgens; neoplasm grade; prostatic neoplasms; testosterone

  Personal Message from Dr. Smith

My primary goal at AntiagingAtlanta is to enhance your quality of life through providing a comprehensive approach to antiaging medicine.

I am committed to providing you with the best Antiaging Medicine program available.

Call me today and schedule your Antiaging Medicine evaluation.


Dr. Randy Smith



Antiaging Atlanta
12600 Deerfield Parkway
Suite 100
Alpharetta, Georgia 30004

Phone: 678-566-3602

Call today today and speak with Dr. Smith to schedule your personal Agntiaging Medicine evaluation.

Getting Started

To unsubscribe to our newsletter email Dr. Smith at:

Dr. Smith